Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience

Measles Clinical Trial

Official title:

Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05614791
• Other study ID #: 2019.10.2.02.075
• Status: Completed
• Start date: January 1, 2019
• Est. completion date: May 30, 2020

Study information

• Verified date: November 2022
• Source: Marmara University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Measles, can be prevented and eliminated by vaccination, is a highly contagious viral disease that can lead to serious complications, disability, and death. As a result of the World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) strategic plans, the annual global incidence of measles decreased by 75% over the period 2000-2015, and the estimated global mortality rate fell by 73%. For the current 2019 period, the European and the Eastern Mediterranean Region has recorded respectively more than two-fold and 1.5-fold increase in reported measles cases. As it is known, no specific antiviral treatment exists for the measles virus therefore, vaccination is still the most effective method of preventing disease.

The aim of this study was to evaluate the measles cases in districts where the refugees live quite intensely.

Description:

Measles, can be prevented and eliminated by vaccination, is a highly contagious viral disease that can lead to serious complications, disability, and death. As a result of the World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) strategic plans, the annual global incidence of measles decreased by 75% over the period 2000-2015, and the estimated global mortality rate fell by 73%. For the current 2019 period, the European and the Eastern Mediterranean Region has recorded respectively more than two-fold and 1.5-fold increase in reported measles cases. As it is known, no specific antiviral treatment exists for the measles virus therefore, vaccination is still the most effective method of preventing disease.

The aim of this study was to evaluate the measles cases in districts where the refugees live quite intensely.

This retrospective study was consecutively enrolled children who were considered as suspicious measles case according to with clinical features and attended in Esenler Gynecology and Pediatrics Hospital Pediatric Clinic between 01 January-30 June 2019.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 30, 2020
• Est. primary completion date: June 30, 2019
• Gender: All
• Age group: 1 Month to 18 Years

Eligibility

Inclusion Criteria:

• The suspicious case of measles

• Measles/Rubella Case Notification and Laboratory request and result form and Measles/ Rubella Case Study form must be filled

• Accept the informed consent form

• Positive Measles Ig M and Measles Ig G laboratory test

Exclusion Criteria:

• Rejected the informed consent form

Related Conditions & MeSH terms

• Measles

Locations

Country	Name	City	State
Turkey	Esenler Maternity and Child Health Hospital	Istanbul	Esenler
Turkey	Haseki Training and Research Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Marmara University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Filia A, Bella A, Del Manso M, Baggieri M, Magurano F, Rota MC. Ongoing outbreak with well over 4,000 measles cases in Italy from January to end August 2017 - what is making elimination so difficult? Euro Surveill. 2017 Sep 14;22(37). pii: 30614. doi: 10.2807/1560-7917.ES.2017.22.37.30614. — View Citation

Lo Vecchio A, Krzysztofiak A, Montagnani C, Valentini P, Rossi N, Garazzino S, Raffaldi I, Di Gangi M, Esposito S, Vecchi B, Melzi ML, Lanari M, Zavarise G, Bosis S, Valenzise M, Cazzato S, Sacco M, Govoni MR, Mozzo E, Cambriglia MD, Bruzzese E, Di Camillo C, Pata D, Graziosi A, Sala D, Magurano F, Villani A, Guarino A, Galli L; SITIP Measles Study Group. Complications and risk factors for severe outcome in children with measles. Arch Dis Child. 2020 Sep;105(9):896-899. doi: 10.1136/archdischild-2018-315290. Epub 2019 Jan 12. — View Citation

Lord H, Kok J, Fletcher S, Alexander K. Is it or is it not? Lessons learned from a case of suspected vaccine strain measles. Aust N Z J Public Health. 2020 Apr;44(2):160-162. doi: 10.1111/1753-6405.12969. Epub 2020 Mar 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluate the effect of measles vaccination status on cost of measles cases	compare the groups costs (Turkish Lira) who fully, partly or not vaccinated	in the first month after the first symptom observed
Other	Evaluate the effect of vitamin A treatment on cost of measles cases	compare the groups costs (Turkish Lira) who get or not get vitamin A treatment	in the first month after the first symptom observed
Primary	Evaluate the effect of measles vaccination status on symptom duration	compare the groups symptom durations (day) who fully, partly or not vaccinated	baseline
Primary	Evaluate the effect of vitamin A treatment on symptom duration	compare the groups symptom durations (day) who get or not get vitamin A treatment	in the first month after the first symptom observed
Secondary	Evaluate the effect of measles vaccination status on leucocyte count	compare the groups leucocyte count who fully, partly or not vaccinated	baseline
Secondary	Evaluate the effect of vitamin A treatment on leucocyte count	compare the groups leucocyte count who get or not get vitamin A treatment	baseline